Omalizumab to Accelerate a Symptom-driven Multi-food OIT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-11

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will determine the dose-related efficacy of a 20-week treatment of omalizumab started 8 weeks before the onset of a symptom-driven multi-food oral immunotherapy (OIT) protocol at decreasing time to OIT maintenance dose. Two dosages of omalizumab will be compared to placebo during an oral immunotherapy protocol for three simultaneous food allergens.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696

Peanut Allergy Multi-food Allergy

COMPLETED PHASE3

Omalizumab Weight-Based Dosing Efficacy Trial

NCT06943534

Allergies Food Allergy

RECRUITING PHASE2

A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis

NCT07027163

Food Hypersensitivity Anaphylaxis

COMPLETED

Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

NCT01510626

Immune System Diseases

COMPLETED PHASE1

Effect of Omalizumab in the Skin of Food Allergy Patients

NCT06618963

Food Allergy Food Allergy in Children

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase 2b, multi-center randomized controlled trial comparing 2 doses of omalizumab to placebo in subjects 6 to 25 years old with multiple food allergies undergoing a symptom-driven multi-food OIT protocol.

Subjects will undergo a screening period involving a DBPCFC to a mix of three allergens which will determine their eligibility and eliciting dose.

Eligible subjects will be randomized to one of 2 omalizumab dosages or placebo at a ratio of 2:2:1 for a total period of 20 weeks.

They will undergo initial food escalation (IFE) to determine their starting food treatment mix dose for three simultaneous food allergens after a pre-treatment period of 8 weeks with the study drug.

Subjects will undergo up-dosing OIT visits at the clinic every two weeks, until a maintenance dose of 1500mg of protein (500mg per food) is reached (primary endpoint).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Food IgE-mediated Allergy Immunotherapy Omalizumab Physiological Effects of Drugs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Omalizumab 16 mg/kg

Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks.

Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug.

Group Type EXPERIMENTAL

Omalizumab 16mg/kg

Intervention Type BIOLOGICAL

Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.

Multi-food oral immunotherapy (OIT)

Intervention Type OTHER

Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.

Omalizumab 8 mg/kg

Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks.

Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug.

Group Type EXPERIMENTAL

Omalizumab 8mg/kg

Intervention Type BIOLOGICAL

Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.

Multi-food oral immunotherapy (OIT)

Intervention Type OTHER

Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.

Placebo

Participants will receive placebo doses for 20 weeks. The doses will be injected every 2 or 4 weeks depending on the weight of the participant.

Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.

Multi-food oral immunotherapy (OIT)

Intervention Type OTHER

Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omalizumab 16mg/kg

Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.

Intervention Type BIOLOGICAL

Omalizumab 8mg/kg

Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.

Intervention Type BIOLOGICAL

Placebo

Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.

Intervention Type BIOLOGICAL

Multi-food oral immunotherapy (OIT)

Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects 6 to 25 years old at screening visit.
2. History of IgE-mediated allergy to at least three foods within the following list: peanut, milk, egg, wheat, oat, soy, barley, rye, buckwheat, hazelnut, pecan, cashew, pistachio, almond, walnut and sesame.
3. Subjects currently following a strict avoidance of these three foods.
4. Positive SPT with a largest wheal diameter ≥ 6 mm to all three foods.
5. Food-specific IgE level greater than 15 kU/L for all three foods
6. Positive DBPCFC to treatment food mix with an eliciting dose ≤ 300 mg of total food protein.
7. Signed informed consent and assent.

Exclusion Criteria

1. Subjects reacting objectively to the placebo during the screening DBPCFC.
2. Severe asthma as defined by GINA 201948.
3. Active or past confirmed eosinophilic oesophagitis.
4. Subject currently under allergen immunotherapy.
5. Subject/parent with excessive anxiety unlikely to cope with study conditions as per investigator's opinion.
6. Subject/parent unwillingness to comply with study requirements.
7. Subject unwillingness to ingest a daily food dose of up to 1500 mg of allergen protein.
8. Inability to discontinue anti-histamine medication prior to study procedures.
9. Known allergy to omalizumab or its excipients.
10. Known allergy to components of the placebo food treatment mix that cannot be substituted without interfering with the blind (e.g.: dates, banana, chocolate syrup)
11. Use of immunosuppression or immunomodulatory drug (including omalizumab) or food oral immunotherapy or investigational treatment or procedure within 1 year.
12. Relative contraindication or inability to use epinephrine auto-injector.
13. Subjects receiving beta-blockers or angiotensin converting-enzyme (ACE) inhibitors.
14. Pregnancy or lactation for the duration of the study.
15. Any condition that is not compatible with the study treatment or procedures as per investigator judgment.

Minimum Eligible Age

6 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No